CN101400363B - 具有增强的稳定性的药物组合物 - Google Patents
具有增强的稳定性的药物组合物 Download PDFInfo
- Publication number
- CN101400363B CN101400363B CN2007800089333A CN200780008933A CN101400363B CN 101400363 B CN101400363 B CN 101400363B CN 2007800089333 A CN2007800089333 A CN 2007800089333A CN 200780008933 A CN200780008933 A CN 200780008933A CN 101400363 B CN101400363 B CN 101400363B
- Authority
- CN
- China
- Prior art keywords
- acid
- peptide
- peptide reagent
- polymeric compositions
- csf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
样品 | 亮丙立德盐 | DLPLG | 药物负荷 |
(mg) | 8515/NMP(mg) | (%,w/w) | |
空白 | 0 | 1000 | 0 |
LA-Ac | 50 | 890 | 5.3 |
LA-MS | 54 | 960 | 5.3 |
LA-HCl-1 | 106 | 940 | 10.1 |
LA-HCl-2 | 41 | 730 | 5.3 |
时间(M) | LA-AC | LA-HCl-1 | LA-HCl-2 | LA-MS |
0 | 100 | 100 | 100 | 100 |
1 | 75 | 99 | 100 | 95 |
2 | 78 | 98 | 97 | 97 |
3 | 86 | 100 | 100 | 100 |
6 | 87 | 99 | 100 | 99 |
12 | 65 | 89 | 89 | 89 |
时间(M) | 空白 | LA-AC | LA-HCI-1 | LA-MS |
0 | 24655 | 23842 | 24369 | 24556 |
1 | 25214 | 24282 | 25203 | 24574 |
3 | 24567 | 22775 | 24833 | 24833 |
6 | 23935 | 21957 | 24661 | 24034 |
12 | 23905 | 18906 | 23837 | 23393 |
18 | 22178 | 16107 | 22802 | 22227 |
时间(M) | 空白 | LA-AC | LA-HCl-1 | LA-HCl-2 | LA-MS |
0 | 24655.0 | 24282 | 24567 | 24468 | 24468 |
1 | 24282.2 | 20526 | 25022 | 25022 | 24832 |
2 | 22969.3 | 15459 | 23230 | 23230 | 22969 |
3 | 23227.7 | 11073 | 23228 | 23311 | 21872 |
6 | ND | 3409 | 18998 | 17952 | 15114 |
12 | 3112.3 | 380 | 4236 | 3388 | 2531 |
样品 | 亮丙立德盐(mg) | DMSO中的DLPLG8515(mg) | 药物负荷(%,w/w) |
空白 | 0 | 4000 | 0 |
LAAc | 200.4 | 4788 | 4 |
LAMS-3 | 200.0 | 4806 | 4 |
LAHCl-3 | 202.8 | 4810 | 4 |
Claims (34)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75989106P | 2006-01-18 | 2006-01-18 | |
US60/759,891 | 2006-01-18 | ||
PCT/US2007/001039 WO2007084460A2 (en) | 2006-01-18 | 2007-01-16 | Pharmaceutical compositions with enhanced stability |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101400363A CN101400363A (zh) | 2009-04-01 |
CN101400363B true CN101400363B (zh) | 2012-08-29 |
Family
ID=38288166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007800089333A Active CN101400363B (zh) | 2006-01-18 | 2007-01-16 | 具有增强的稳定性的药物组合物 |
Country Status (14)
Country | Link |
---|---|
US (5) | US20070196416A1 (zh) |
EP (1) | EP1984009B1 (zh) |
JP (1) | JP5242415B2 (zh) |
KR (2) | KR101728868B1 (zh) |
CN (1) | CN101400363B (zh) |
AU (1) | AU2007207618B2 (zh) |
CA (1) | CA2637569C (zh) |
DK (1) | DK1984009T3 (zh) |
ES (1) | ES2397712T3 (zh) |
HK (1) | HK1126975A1 (zh) |
MX (1) | MX2008009125A (zh) |
RU (1) | RU2427383C2 (zh) |
SI (1) | SI1984009T1 (zh) |
WO (1) | WO2007084460A2 (zh) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
JP5143131B2 (ja) | 2006-05-30 | 2013-02-13 | インターシア セラピューティクス,インコーポレイティド | 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ |
PL2359808T3 (pl) | 2006-08-09 | 2013-10-31 | Intarcia Therapeutics Inc | Osmotyczne systemy dostawcze i zespoły tłokowe |
EP1917971A1 (en) * | 2006-10-27 | 2008-05-07 | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) | Substained release formulations comprising very low molecular weight polymers |
US8946200B2 (en) | 2006-11-02 | 2015-02-03 | Southwest Research Institute | Pharmaceutically active nanosuspensions |
CA2683610C (en) | 2007-04-23 | 2013-01-08 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
CA2686137C (en) | 2007-05-18 | 2021-01-12 | Durect Corporation | Improved depot formulations |
CA2687979C (en) | 2007-05-25 | 2017-07-04 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of risperidone compounds |
JP5584132B2 (ja) * | 2007-11-15 | 2014-09-03 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 疼痛の治療のための前立腺酸性ホスファターゼ |
US9161943B2 (en) * | 2007-12-31 | 2015-10-20 | Industrial Technology Research Institute | Sustained release composition and manufacturing method thereof |
US20090196905A1 (en) * | 2008-02-06 | 2009-08-06 | Spada Lon T | Stabilization of mitochondrial membranes in ocular diseases and conditions |
DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
US8404850B2 (en) | 2008-03-13 | 2013-03-26 | Southwest Research Institute | Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors |
GB0810990D0 (en) * | 2008-06-16 | 2008-07-23 | Q Chip Ltd | Device and method of making solid beads |
JP5622725B2 (ja) * | 2008-06-25 | 2014-11-12 | エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド.Endo Pharmaceuticals Solutionsinc. | エキセナチド及び他のポリペプチド類の持続的送達 |
US8722706B2 (en) | 2008-08-15 | 2014-05-13 | Southwest Research Institute | Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts |
EP2946770A1 (en) * | 2008-08-29 | 2015-11-25 | Genzyme Corporation | Controlled-released peptide formulations |
US8309134B2 (en) | 2008-10-03 | 2012-11-13 | Southwest Research Institute | Modified calcium phosphate nanoparticle formation |
KR101823699B1 (ko) | 2009-09-28 | 2018-01-30 | 인타르시아 세라퓨틱스 인코포레이티드 | 실질 항정상태 약물 전달의 신속 확립 및/또는 종결 |
WO2011060352A1 (en) | 2009-11-16 | 2011-05-19 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of melanocortin receptor ligands |
US9028873B2 (en) | 2010-02-08 | 2015-05-12 | Southwest Research Institute | Nanoparticles for drug delivery to the central nervous system |
RU2523566C2 (ru) * | 2010-03-15 | 2014-07-20 | Ипсен Фарма С.А.С. | Фармацевтическая композиция лигандов рецепторов секретагогов гормона роста |
CN107260684A (zh) * | 2010-03-29 | 2017-10-20 | 赢创有限公司 | 用于在局部给药位点改进药物组合物的滞留的组合物和方法 |
CN101810583B (zh) * | 2010-04-09 | 2013-09-11 | 佟丽 | Hiv融合抑制剂缓释微球 |
US9364518B2 (en) * | 2010-06-24 | 2016-06-14 | Torrent Pharmaceuticals Limited | Pharmaceutical composition containing goserelin for in-situ implant |
US20120046225A1 (en) * | 2010-07-19 | 2012-02-23 | The Regents Of The University Of Colorado, A Body Corporate | Stable glucagon formulations for the treatment of hypoglycemia |
RU2446173C1 (ru) * | 2010-08-13 | 2012-03-27 | Зао "Биокад" | Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе |
MX2013002045A (es) * | 2010-08-23 | 2013-10-17 | Yissum Res Dev Co | Composiciones para suministro gastrico de agentes activos. |
CN101934068B (zh) * | 2010-09-26 | 2012-07-25 | 武汉华龙生物制药有限公司 | 胸腺肽注射液的制备方法 |
GB201016436D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Method of making solid beads |
GB201016433D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Apparatus and method for making solid beads |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
CN102145160A (zh) * | 2011-03-07 | 2011-08-10 | 深圳市健元医药科技有限公司 | 一种lhrh拮抗剂注射用的缓释植入制剂 |
AU2012225268B2 (en) | 2011-03-10 | 2016-10-20 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of peptide drugs |
TR201815766T4 (tr) | 2011-06-23 | 2018-11-21 | British American Tobacco Investments Ltd | Polilaktid fiberleri içeren filtre materyali. |
GB201112402D0 (en) | 2011-07-19 | 2011-08-31 | British American Tobacco Co | Cellulose acetate compositions |
ES2574761T3 (es) | 2011-10-31 | 2016-06-21 | Xeris Pharmaceuticals, Inc. | Formulaciones para el tratamiento de la diabetes |
GB201208293D0 (en) | 2012-05-11 | 2012-06-20 | Circassia Ltd | Hydrochlorice salt of peptide |
US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
JP2016503771A (ja) | 2012-12-21 | 2016-02-08 | サノフイ | エキセンジン−4誘導体 |
US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
US9737605B2 (en) | 2013-03-11 | 2017-08-22 | Durect Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
US9040034B2 (en) | 2013-04-09 | 2015-05-26 | International Business Machines Corporation | Vitamin functionalized gel-forming block copolymers for biomedical applications |
US9642893B2 (en) * | 2013-07-03 | 2017-05-09 | Joseph Cummins | Method for reducing injury and stabilizing muscle using orally administered interferon |
US9757330B2 (en) | 2013-10-18 | 2017-09-12 | Industrial Technology Research Institute | Recipe for in-situ gel, and implant, drug delivery system formed thereby |
CN105764491A (zh) | 2013-12-09 | 2016-07-13 | 度瑞公司 | 药物活性剂复合物、聚合物复合物,以及包括其的组合物和方法 |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
CN109498815B (zh) * | 2013-12-30 | 2022-07-22 | 江苏众红生物工程创药研究院有限公司 | 重组人激肽释放酶的化学修饰物及其应用 |
CN106132430A (zh) * | 2014-02-06 | 2016-11-16 | Xeris药物公司 | 稳定肽制剂及其制备方法 |
RU2557925C1 (ru) * | 2014-03-17 | 2015-07-27 | Новиков Сергей Викторович | Биодеградируемый многослойный имплант для введения лекарственных веществ в витреальную полость глаза |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
EP3131532A1 (de) | 2014-04-16 | 2017-02-22 | Veyx-Pharma GmbH | Veterinärpharmazeutische zusammensetzung und deren verwendung |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
AU2015300944B2 (en) | 2014-08-06 | 2019-07-11 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US20160106804A1 (en) * | 2014-10-15 | 2016-04-21 | Yuhua Li | Pharmaceutical composition with improved stability |
WO2016059592A1 (en) * | 2014-10-16 | 2016-04-21 | Piramal Enterprises Limited | Stable injectable composition of peptide drugs and process for its preparation |
US20170239335A1 (en) * | 2014-10-16 | 2017-08-24 | Piramal Enterprises Limited | Stable injectable composition of pharmaceutically active agents and process for its preparation |
US10046058B2 (en) | 2014-12-02 | 2018-08-14 | Rezolute, Inc. | Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates |
MX2017015504A (es) | 2015-06-03 | 2018-05-15 | Intarcia Therapeutics Inc | Sistemas de colocacion y remoción de implante. |
US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
EA036951B1 (ru) * | 2015-08-03 | 2021-01-19 | Толмар Интернэшнл Лимитед | Жидкая полимерная система доставки для длительного введения лекарственных средств |
US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
JP7093559B2 (ja) * | 2016-04-12 | 2022-06-30 | トライジェミナ, インコーポレイテッド | マグネシウム含有オキシトシン製剤および使用の方法 |
AU2017268161B2 (en) | 2016-05-16 | 2020-03-12 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
AU2018206539A1 (en) | 2017-01-03 | 2019-07-18 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
EP4011386A1 (en) * | 2017-01-31 | 2022-06-15 | Veru Inc. | Compositions and methods for long term release of gonadotropin-releasing hormone (gnrh) antagonists |
AU2018275686B2 (en) | 2017-06-02 | 2024-02-01 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
KR102522654B1 (ko) * | 2017-12-18 | 2023-04-17 | 포시 파마슈티컬스 컴퍼니 리미티드 | 선택된 방출 기간을 갖는 약제학적 조성물 |
US20210205404A1 (en) * | 2018-05-16 | 2021-07-08 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition of kor receptor agonist |
CN109316371B (zh) * | 2018-09-21 | 2021-09-03 | 珀莱雅化妆品股份有限公司 | 一种芹菜素缓释制剂的制备方法 |
KR20200051916A (ko) * | 2018-11-05 | 2020-05-14 | 주식회사 메디포럼제약 | 고세렐린을 포함하는 실리카 하이드로겔 조성물 |
JP2022525019A (ja) * | 2019-03-15 | 2022-05-11 | ノヴォ ノルディスク アー/エス | Glp-1ペプチドを噴霧乾燥するためのプロセス |
KR102249104B1 (ko) * | 2019-04-30 | 2021-05-07 | (주)인벤티지랩 | 데슬로렐린을 포함하는 서방성 마이크로 입자 및 이의 제조 방법 |
EA202193257A1 (ru) * | 2019-05-27 | 2022-03-10 | Толмар Интернэшнл Лимитед | Композиции ацетата лейпролида и способы их применения для лечения рака молочной железы |
CA3140681A1 (en) * | 2019-06-07 | 2020-12-10 | President And Fellows Of Harvard College | Compositions and methods relating to erythrocytes with adhered particles |
MX2022005494A (es) * | 2019-11-08 | 2022-08-11 | Lyndra Therapeutics Inc | Sistemas de residencia gastrica para la administracion de agentes activos. |
EP4380546A1 (en) | 2021-08-05 | 2024-06-12 | MedinCell S.A. | Pharmaceutical composition |
WO2024117740A1 (ko) * | 2022-11-28 | 2024-06-06 | 동국제약 주식회사 | 인-시튜 임플란트를 형성할 수 있는 서방형 약학 조성물 및 이의 제조방법 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020164365A1 (en) * | 1995-04-13 | 2002-11-07 | Shalaby Shalaby W. | Multifaceted compositions for post-surgical adhesion prevention |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US444340A (en) * | 1891-01-06 | Coupling-shoe | ||
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4443340A (en) | 1981-10-09 | 1984-04-17 | Betz Laboratories, Inc. | Control of iron induced fouling in water systems |
JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
US6312679B1 (en) * | 1986-08-18 | 2001-11-06 | The Dow Chemical Company | Dense star polymer conjugates as dyes |
DE3708916A1 (de) | 1987-03-19 | 1988-09-29 | Boehringer Ingelheim Kg | Verfahren zur reinigung resorbierbarer polyester |
US4938763B1 (en) * | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5702716A (en) * | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US5487897A (en) | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
JPH0818999B2 (ja) * | 1990-01-05 | 1996-02-28 | 藤沢薬品工業株式会社 | インシュリン様成長因子iの乾燥製剤 |
DE4004430A1 (de) * | 1990-02-09 | 1991-08-14 | Schering Ag | Aus polyaldehyden aufgebaute kontrastmittel |
DE69129770T2 (de) | 1990-04-13 | 1998-11-19 | Takeda Chemical Industries Ltd | Biologisch abbaubare hochmolekulare Polymere, ihre Herstellung und ihre Verwendung |
USRE37950E1 (en) | 1990-04-24 | 2002-12-31 | Atrix Laboratories | Biogradable in-situ forming implants and methods of producing the same |
IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
US5529914A (en) * | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
US5410016A (en) * | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
EP0572675B1 (en) * | 1991-12-19 | 1999-09-22 | Mitsui Chemicals, Inc. | Polyhydroxy carboxylic acid and production thereof |
EP0560014A1 (en) * | 1992-03-12 | 1993-09-15 | Atrix Laboratories, Inc. | Biodegradable film dressing and method for its formation |
US5338822A (en) | 1992-10-02 | 1994-08-16 | Cargill, Incorporated | Melt-stable lactide polymer composition and process for manufacture thereof |
US5242910A (en) * | 1992-10-13 | 1993-09-07 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
JP2944419B2 (ja) * | 1993-05-10 | 1999-09-06 | ノバルティス アクチエンゲゼルシャフト | 持続性遊離組成物中の薬理学的活性成分の安定 |
AU682061B2 (en) | 1993-09-17 | 1997-09-18 | Novo Nordisk A/S | Acylated insulin |
US5681873A (en) * | 1993-10-14 | 1997-10-28 | Atrix Laboratories, Inc. | Biodegradable polymeric composition |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
ES2171186T3 (es) | 1994-04-08 | 2002-09-01 | Atrix Lab Inc | Composiciones liquidas de difusion. |
US5478921A (en) | 1994-08-25 | 1995-12-26 | United States Surgical Corporation | Method of purifying bioabsorable polymer |
US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
US5698213A (en) * | 1995-03-06 | 1997-12-16 | Ethicon, Inc. | Hydrogels of absorbable polyoxaesters |
US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
US7033608B1 (en) | 1995-05-22 | 2006-04-25 | The United States Of America As Represented By The Secretary Of The Army | “Burst-free” sustained release poly-(lactide/glycolide) microspheres |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
PT944648E (pt) | 1996-08-30 | 2007-06-26 | Novo Nordisk As | Derivados do glp-1. |
WO1998008872A1 (en) | 1996-08-30 | 1998-03-05 | Novo Nordisk A/S | Glp-2 derivatives |
US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
TW577759B (en) * | 1997-04-18 | 2004-03-01 | Ipsen Pharma Biotech | Sustained release compositions in the form of microcapsules or implants and the process for their preparation |
JP2001522814A (ja) * | 1997-11-07 | 2001-11-20 | カイロン コーポレイション | 増大されたigf−i溶解性を提供する組成物 |
AU3247799A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
US6410044B1 (en) * | 1998-03-19 | 2002-06-25 | Surmodics, Inc. | Crosslinkable macromers |
US6261583B1 (en) | 1998-07-28 | 2001-07-17 | Atrix Laboratories, Inc. | Moldable solid delivery system |
US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
US6143314A (en) * | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
US6355657B1 (en) * | 1998-12-30 | 2002-03-12 | Atrix Laboratories, Inc. | System for percutaneous delivery of opioid analgesics |
DE19908753C2 (de) | 1999-02-20 | 2003-10-02 | Jenapharm Gmbh | Bioabbaubare, injizierbare Oligomer-Polymer-Zusammensetzung |
US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
FR2806727A1 (fr) * | 2000-03-23 | 2001-09-28 | Pf Medicament | Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable |
US6626870B1 (en) | 2000-03-27 | 2003-09-30 | Artix Laboratories, Inc. | Stoppering method to maintain sterility |
EP1310517B2 (en) | 2000-08-07 | 2010-11-17 | Wako Pure Chemical Industries, Ltd. | Lactic acid polymer and process for producing the same |
US8470359B2 (en) | 2000-11-13 | 2013-06-25 | Qlt Usa, Inc. | Sustained release polymer |
TWI225416B (en) | 2001-06-29 | 2004-12-21 | Takeda Chemical Industries Ltd | Sustained-release composition and process for producing the same |
TW200526267A (en) | 2001-06-29 | 2005-08-16 | Takeda Chemical Industries Ltd | Controlled release composition and method of producing the same |
US7098305B2 (en) | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
IL166418A0 (en) | 2002-07-31 | 2006-01-15 | Alza Corp | Injectable depot compositions and uses thereof |
US6966990B2 (en) | 2002-10-11 | 2005-11-22 | Ferro Corporation | Composite particles and method for preparing |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
DK1660039T3 (en) | 2003-07-18 | 2017-01-16 | Oakwood Laboratories L L C | PREVENTION OF REDUCTION OF THE POLYMER MOLECULE WEIGHT, THE PREPARATION OF PURPOSES AND GELING IN POLYMER COMPOSITIONS |
WO2005067889A1 (en) * | 2003-12-30 | 2005-07-28 | Durect Corporation | Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh |
US7989490B2 (en) * | 2004-06-02 | 2011-08-02 | Cordis Corporation | Injectable formulations of taxanes for cad treatment |
PT1786400E (pt) * | 2004-08-12 | 2009-06-19 | Quest Pharmaceutical Services | Composições farmacêuticas para a libertação controlada de compostos biologicamente activos |
US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
RS53890B1 (en) | 2004-11-10 | 2015-08-31 | Tolmar Therapeutics, Inc. | STABILIZED POLYMER DELIVERY SYSTEM |
US7342048B2 (en) | 2005-04-28 | 2008-03-11 | Nipro Corporation | Bioabsorbable pharmaceutical formulation |
US8076448B2 (en) | 2006-10-11 | 2011-12-13 | Tolmar Therapeutics, Inc. | Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction |
ES2516695T3 (es) | 2006-10-11 | 2014-10-31 | Tolmar Therapeutics, Inc. | Preparación de poliésteres biodegradables con bajas propiedades de absorción rápida mediante extracción de fluido supercrítico |
HUE025842T2 (en) | 2007-02-15 | 2016-04-28 | Tolmar Therapeutics Inc | Poly (lactide / glycolide) with reduced fracture properties and methods for producing polymers |
EP2309982A2 (en) | 2008-06-03 | 2011-04-20 | Tolmar Therapeutics, Inc. | Controlled release copolymer formulation with improved release kinetics |
WO2009148581A1 (en) | 2008-06-03 | 2009-12-10 | Qlt Usa, Inc. | Biocompatible oligomer-polymer compositions |
UA122135C2 (uk) | 2014-12-04 | 2020-09-25 | Толмар Терап'Ютикс, Інк. | Система самозамикального нарізного поршня шприца |
EA036951B1 (ru) | 2015-08-03 | 2021-01-19 | Толмар Интернэшнл Лимитед | Жидкая полимерная система доставки для длительного введения лекарственных средств |
-
2007
- 2007-01-16 WO PCT/US2007/001039 patent/WO2007084460A2/en active Search and Examination
- 2007-01-16 KR KR1020087020179A patent/KR101728868B1/ko active IP Right Grant
- 2007-01-16 EP EP07718050A patent/EP1984009B1/en active Active
- 2007-01-16 DK DK07718050.3T patent/DK1984009T3/da active
- 2007-01-16 CN CN2007800089333A patent/CN101400363B/zh active Active
- 2007-01-16 CA CA2637569A patent/CA2637569C/en active Active
- 2007-01-16 SI SI200731130T patent/SI1984009T1/sl unknown
- 2007-01-16 US US11/653,636 patent/US20070196416A1/en not_active Abandoned
- 2007-01-16 AU AU2007207618A patent/AU2007207618B2/en active Active
- 2007-01-16 KR KR1020157002423A patent/KR20150017777A/ko not_active Application Discontinuation
- 2007-01-16 JP JP2008551315A patent/JP5242415B2/ja active Active
- 2007-01-16 ES ES07718050T patent/ES2397712T3/es active Active
- 2007-01-16 MX MX2008009125A patent/MX2008009125A/es active IP Right Grant
- 2007-01-16 RU RU2008129201/15A patent/RU2427383C2/ru active
-
2009
- 2009-07-15 HK HK09106419.1A patent/HK1126975A1/xx unknown
-
2016
- 2016-08-06 US US15/230,413 patent/US9572857B2/en active Active
-
2017
- 2017-01-13 US US15/406,321 patent/US9744207B2/en active Active
- 2017-07-27 US US15/661,066 patent/US10251956B2/en active Active
-
2019
- 2019-04-05 US US16/376,028 patent/US10646572B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020164365A1 (en) * | 1995-04-13 | 2002-11-07 | Shalaby Shalaby W. | Multifaceted compositions for post-surgical adhesion prevention |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101400363B (zh) | 具有增强的稳定性的药物组合物 | |
CN101035512B (zh) | 用于生物活性化合物可控制释放递送的药物组合物 | |
BRPI0715469A2 (pt) | composiÇÕes farmacÊuticas para a liberaÇço sustentada de peptÍdeos | |
NZ239381A (en) | A microcapsule designed for zero order release of a polypeptide | |
WO2004073749A1 (ja) | 徐放性製剤用の分散剤 | |
US20230346877A1 (en) | Pharmaceutical Compositions having a Selected Release Duration | |
JP4683319B2 (ja) | 徐放性製剤用の分散剤 | |
TWI376241B (en) | Pharmaceutical compositions with enhanced stability | |
NZ766167B2 (en) | Pharmaceutical compositions having a selected release duration | |
BRPI0706558B1 (pt) | Composição polimérica injetável, métodos para preparar uma composição polimérica injetável e métodos para preparar um sal de um análogo de hormônio de liberação de hormônio luteínico (lhrh) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1126975 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: YICHANG BIOCHEMICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: QUEST PHARMACEUTICAL SERVICES Effective date: 20130222 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130222 Address after: Cayman Islands Patentee after: Yat Chang Biochemical Technology Co., Ltd. Address before: Delaware Patentee before: Qps LLC |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1126975 Country of ref document: HK |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150930 Address after: Taipei City, Taiwan, China Patentee after: Yat biological Polytron Technologies Inc Address before: Cayman Islands Patentee before: Yat Chang Biochemical Technology Co., Ltd. |